Mark A. Marzinke

机构：Johns Hopkins University, Johns Hopkins Medicine, Columbia University · ORCID：0000-0003-1670-8786

发表论文 297 篇 · 总被引 10861 次 · h-index 49

代表论文

• Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study (2025 · The Lancet HIV · 被引 12)
• Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial (2025 · The Lancet HIV · 被引 8)
• Recommendations for Interpreting Intraerythrocytic Tenofovir Diphosphate and Emtricitabine Triphosphate for HIV-1 Preexposure Prophylaxis Adherence Assessment (2025 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 6)
• Prevalence of Illicit Drug Detection in 5 US Cities Among Out-of-Treatment People Who Inject Drugs (2026 · JAMA Network Open · 被引 3)
• Estimation of Prevention-Effective CAB-LA Concentrations Among Men Who Have Sex With Men (MSM) and Transgender Women (TGW) in HPTN 083 (2025 · The Journal of Infectious Diseases · 被引 3)
• Safety outcomes among infants whose mothers used the dapivirine vaginal ring or oral PrEP during pregnancy (MTN-042/DELIVER): a randomised phase 3b study (2025 · The Lancet HIV · 被引 3)